Glatimyl: Uses, Dosage & Side Effects

What Is Glatimyl and What Is It Used For?

Glatimyl contains the active substance glatiramer acetate, a unique synthetic polypeptide composed of the acetate salts of four naturally occurring amino acids: L-glutamic acid, L-alanine, L-tyrosine, and L-lysine, in a specific molar ratio of 0.141, 0.427, 0.095, and 0.338, respectively. The resulting molecule has an average molecular weight of 5,000–9,000 daltons and is structurally related to myelin basic protein (MBP), one of the principal protein components of the myelin sheath that surrounds and insulates nerve fibers in the central nervous system. This structural similarity to MBP is central to the drug’s immunomodulatory mechanism of action.

Multiple sclerosis is a chronic autoimmune disease in which the immune system mistakenly attacks the myelin sheath surrounding neurons in the brain and spinal cord. This leads to inflammation, demyelination, and axonal damage, resulting in a wide range of neurological symptoms including vision problems, muscle weakness, numbness, fatigue, cognitive impairment, and difficulties with coordination and balance. The relapsing-remitting form of MS (RRMS) is characterized by clearly defined episodes of new or worsening neurological symptoms (relapses) followed by periods of partial or complete recovery (remissions). Approximately 85% of MS patients are initially diagnosed with RRMS.

Glatiramer acetate exerts its therapeutic effects through a complex and multifaceted immunomodulatory mechanism that has been elucidated over decades of research. Rather than broadly suppressing the immune system, glatiramer acetate modulates specific immune pathways involved in the autoimmune attack on myelin. The primary mechanisms include: (1) shifting the T-helper cell balance from pro-inflammatory Th1 cells that produce cytokines such as interferon-gamma and tumor necrosis factor-alpha toward anti-inflammatory Th2 cells that produce cytokines such as interleukin-4, interleukin-5, and interleukin-10; (2) inducing the generation of glatiramer acetate-specific regulatory T cells (Tregs) that cross-react with myelin antigens and suppress local inflammatory responses in the central nervous system through a process known as bystander suppression; (3) promoting the production of neurotrophic factors, particularly brain-derived neurotrophic factor (BDNF), by both T cells and neurons, which may contribute to neuroprotection and repair; and (4) modulating antigen-presenting cell function by shifting monocytes and dendritic cells toward an anti-inflammatory phenotype.

The clinical development of glatiramer acetate began with the landmark pivotal trial published by Johnson and colleagues in 1995, which randomized 251 patients with RRMS to receive either glatiramer acetate 20 mg/day subcutaneously or placebo for two years. The study demonstrated a statistically significant 29% reduction in the mean annualized relapse rate (ARR) with glatiramer acetate (1.19 relapses per year with placebo versus 0.84 with glatiramer acetate; p = 0.007). Additionally, a significantly greater proportion of patients in the glatiramer acetate group remained relapse-free during the study period. These findings established glatiramer acetate as an effective disease-modifying therapy for RRMS and led to its approval by the U.S. Food and Drug Administration (FDA) in 1996.

Subsequent clinical trials have further characterized the efficacy of glatiramer acetate. The European/Canadian Glatiramer Acetate Study (known as the 9006 study), a large multicenter trial involving 943 patients, confirmed the relapse-rate reduction and additionally demonstrated a significant effect on MRI measures of disease activity, including a reduction in the number of new T2 lesions and gadolinium-enhancing lesions on brain MRI. The PreCISe trial showed that glatiramer acetate significantly delayed the conversion from a clinically isolated syndrome (CIS) — the first clinical episode suggestive of MS — to clinically definite MS by 45%, supporting its use early in the disease course.

One of the most compelling aspects of glatiramer acetate’s evidence base is the availability of exceptionally long-term follow-up data. The open-label extension of the original pivotal trial has provided continuous efficacy and safety data spanning over 20 years. These long-term data have shown sustained reductions in relapse rates, a low rate of disability progression as measured by the Expanded Disability Status Scale (EDSS), and an excellent long-term safety profile with no evidence of cumulative toxicity, opportunistic infections, or increased malignancy risk.

What Should You Know Before Taking Glatimyl?

Contraindications

The primary contraindication to Glatimyl is known hypersensitivity (allergy) to glatiramer acetate or to mannitol, an excipient used in the formulation. If you have previously experienced an allergic reaction to glatiramer acetate or any product containing mannitol, you must not use Glatimyl. Hypersensitivity reactions, while uncommon, have included anaphylaxis, bronchospasm, urticaria, and angioedema in post-marketing surveillance.

It is important to note that glatiramer acetate is a complex mixture of polypeptides, and as with any protein-based therapy, there is a potential for immunogenic reactions. However, the development of anti-glatiramer acetate antibodies has not been associated with loss of efficacy or increased adverse events in clinical studies. Unlike some other disease-modifying therapies for MS, glatiramer acetate does not carry contraindications related to specific infections (such as progressive multifocal leukoencephalopathy), malignancies, or severe hepatic or renal impairment.

Warnings and Precautions

Before starting Glatimyl, discuss the following with your healthcare provider:

• Cardiac conditions: Patients with pre-existing cardiac disease should be informed about the potential for immediate post-injection reactions that may include chest pain and palpitations. While these reactions are generally benign and self-limiting, patients with underlying coronary artery disease, arrhythmias, or congestive heart failure should be monitored more closely during the initial period of treatment. There have been rare post-marketing reports of serious cardiovascular events temporally associated with the IPIR, although a causal relationship has not been established.
• Lipoatrophy: Localized loss of subcutaneous fat tissue (lipoatrophy) has been reported at injection sites in some patients receiving glatiramer acetate. This condition may result in permanent cosmetic disfigurement with visible indentations or depressions in the skin. Lipoatrophy is thought to result from chronic localized inflammatory damage to subcutaneous adipose tissue. To minimize the risk, patients should rigorously rotate injection sites and avoid injecting into areas that already show signs of lipoatrophy. Once lipoatrophy develops, do not inject into the affected area again.
• Skin necrosis: Rare cases of injection site necrosis have been reported. This may present as an area of darkened, hardened skin that may be painful. If you notice signs of necrosis at any injection site, discontinue injections at that site and contact your healthcare provider.
• Hepatic reactions: Rare cases of hepatic injury, including hepatitis, jaundice, and hepatic failure, have been reported during post-marketing surveillance. Patients should be advised to report symptoms such as unexplained nausea, vomiting, abdominal pain, fatigue, anorexia, jaundice, or dark urine to their physician. Although routine liver function monitoring is not required, liver tests should be performed if hepatic injury is clinically suspected.

Pregnancy and Breastfeeding

The safety of glatiramer acetate during pregnancy has not been definitively established through adequate and well-controlled studies in humans. Animal reproduction studies (rats and rabbits) have not revealed evidence of teratogenicity or adverse effects on embryo-fetal development at clinically relevant doses. Post-marketing data from pregnancy registries and observational studies involving several thousand exposed pregnancies have not indicated an increased risk of major congenital malformations, spontaneous abortions, or adverse neonatal outcomes compared with the general MS population or the general population.

Despite these reassuring observations, glatiramer acetate should only be used during pregnancy if the potential benefit to the mother justifies the potential risk to the fetus. Many neurologists consider glatiramer acetate to be among the disease-modifying therapies with the most favorable safety data in pregnancy, and some guidelines suggest that it may be continued during pregnancy in women at high risk of disease reactivation, following a thorough individual benefit-risk assessment. Discuss your specific situation with your neurologist if you are pregnant, planning to become pregnant, or discover you are pregnant while using Glatimyl.

It is not known whether glatiramer acetate or its metabolites are excreted in human breast milk. Because many drugs are excreted in human milk, caution should be exercised when Glatimyl is administered to a nursing woman. However, given the large molecular weight of glatiramer acetate and its expected degradation in the gastrointestinal tract, significant systemic absorption by a breastfed infant is considered unlikely. Some clinical guidelines classify glatiramer acetate as compatible with breastfeeding, but the decision should be made in consultation with your healthcare provider, weighing the benefits of breastfeeding against the potential risks.

How Does Glatimyl Interact with Other Drugs?

Glatiramer acetate has a unique pharmacological profile that makes clinically significant drug interactions unlikely. Unlike small-molecule drugs that are absorbed into the systemic circulation and metabolized by hepatic cytochrome P450 (CYP) enzymes, glatiramer acetate is a large polypeptide that is thought to be substantially hydrolyzed locally at the subcutaneous injection site. It does not appear to reach the systemic circulation in pharmacologically significant concentrations, and its degradation products are amino acids and small peptides that enter normal metabolic pathways. As a result, glatiramer acetate is not expected to affect the metabolism of co-administered medications through CYP enzyme inhibition or induction, nor is it expected to be affected by CYP enzyme modulators.

No formal pharmacokinetic drug interaction studies have been conducted with glatiramer acetate. However, in clinical trials, patients were permitted to use concomitant medications, and no significant interactions were identified. The following considerations apply to specific drug classes:

During clinical trials, glatiramer acetate was used concurrently with baclofen, gabapentin, amantadine, carbamazepine, antidepressants, urinary anticholinergics, and various other symptomatic medications commonly prescribed in MS without evidence of clinically significant interactions. Patients receiving glatiramer acetate should always inform their healthcare provider about all medications they are taking, including prescription drugs, over-the-counter medications, herbal supplements, and vitamins, so that potential interactions can be assessed on an individual basis.

What Is the Correct Dosage of Glatimyl?

Adults

Glatiramer acetate is also available in a higher-strength formulation of 40 mg/mL, administered three times per week with at least 48 hours between doses (e.g., Monday, Wednesday, Friday). However, the Glatimyl product specifically discussed here is the 20 mg/mL daily formulation. The choice between daily and three-times-weekly regimens should be made in consultation with your neurologist based on individual clinical considerations and patient preference.

Proper injection technique is essential for maximizing the efficacy of Glatimyl and minimizing injection site reactions. Follow these steps for each injection:

1. Preparation: Remove the pre-filled syringe from the refrigerator and allow it to reach room temperature for approximately 20 minutes. Cold injections are more likely to cause pain and local reactions. Do not use external heat sources (such as a microwave or hot water) to warm the syringe.
2. Site selection: Choose an injection site from the seven recommended areas: back of upper arms (2), abdomen (avoiding the 2-inch area around the navel) (1), upper outer thighs (2), and hips/upper outer buttocks (2). Use a systematic rotation pattern to ensure that you do not inject into the same site more frequently than once every seven days.
3. Site preparation: Wash your hands thoroughly with soap and water. Clean the chosen injection site with an alcohol swab and allow it to dry completely before injecting. Do not inject into areas that are red, swollen, tender, hard, scarred, bruised, or show signs of lipoatrophy (visible depressions in the skin).
4. Injection: Remove the needle cap by pulling it straight off. Pinch a fold of skin at the injection site. Insert the needle at a 90-degree angle (or 45-degree angle for patients with very little subcutaneous tissue). Depress the plunger slowly and steadily until the syringe is empty. Hold the needle in place for a few seconds before withdrawing.
5. Post-injection: Apply gentle pressure to the injection site with a clean dry cotton ball or gauze for a few seconds. Do not rub the site. Dispose of the used syringe and needle in an approved sharps disposal container immediately.

Children

Elderly

Missed Dose

If you miss a dose of Glatimyl, take it as soon as you remember on the same day. If you do not remember until the next day, skip the missed dose and continue with your regular dosing schedule. Do not inject two doses on the same day to make up for a missed dose. Occasional missed doses are unlikely to significantly affect the overall efficacy of treatment, but consistent daily administration is recommended for optimal benefit. If you frequently forget doses, consider setting a daily reminder or alarm, or discuss alternative dosing schedules (such as the 40 mg three-times-weekly formulation) with your neurologist.

Overdose

Cases of overdose with glatiramer acetate have been reported during post-marketing surveillance, including cases of accidental administration of multiple daily doses. In reported overdose cases, no serious adverse events beyond those already described for the standard dose (injection site reactions and immediate post-injection reactions) were observed. There is no specific antidote for glatiramer acetate overdose. In the event of an overdose, patients should be monitored and treated symptomatically as needed. Contact your healthcare provider, local poison control center, or emergency medical services if you suspect an overdose.

What Are the Side Effects of Glatimyl?

Like all medicines, Glatimyl can cause side effects, although not everyone who takes it will experience them. Glatiramer acetate has been extensively studied in clinical trials involving thousands of patients and has accumulated over 25 years of post-marketing surveillance data, providing one of the most comprehensive safety databases of any MS therapy. The overall safety profile is favorable, with the majority of adverse events being localized injection site reactions or transient systemic reactions that typically do not require treatment discontinuation.

In the pivotal clinical trials, the discontinuation rate due to adverse events was approximately 7–8% in the glatiramer acetate group compared with 3–4% in the placebo group, with injection site reactions being the most common reason for discontinuation. Long-term open-label extension studies spanning over 15 years have not revealed any new safety signals, evidence of cumulative toxicity, or increased incidence of opportunistic infections or malignancies.

Injection site reactions are the most frequently reported adverse events with glatiramer acetate. In clinical trials, injection site reactions occurred in approximately 50–70% of patients receiving glatiramer acetate compared with 10–30% of patients receiving placebo. The most common injection site reactions include erythema (redness), pain, pruritus (itching), mass or induration (lumps), and edema (swelling). These reactions are generally mild to moderate in severity, begin within minutes of injection, and typically resolve within minutes to hours without specific treatment. The frequency and severity of injection site reactions tend to decrease over the first few months of treatment as patients become accustomed to the injections and refine their injection technique.

Immediate post-injection reactions (IPIR) are a distinctive feature of glatiramer acetate therapy. Approximately 16% of patients experience at least one IPIR during the course of treatment. These reactions typically begin within seconds to minutes of injection and may include one or more of the following symptoms: flushing (vasodilation), chest tightness or pain, palpitations, tachycardia, dyspnea (shortness of breath), throat constriction, anxiety, and urticaria. IPIRs are generally self-limiting, resolving spontaneously within 15–30 minutes without specific treatment. They can occur at any time during treatment and are unpredictable — a patient may have an IPIR after one injection and not after subsequent injections. IPIRs are not allergic reactions and are not predictive of anaphylaxis. The exact mechanism is not fully understood but may involve local release of vasoactive substances from mast cells or other immune cells at the injection site.

Lipoatrophy is an important long-term adverse effect of glatiramer acetate that patients should be aware of. It manifests as localized, permanent depressions or indentations in the skin due to loss of subcutaneous fat tissue at and around injection sites. Lipoatrophy may develop gradually over months to years of treatment and can be cosmetically distressing for patients. The incidence in clinical practice is estimated at 2–5% of patients, although rates may be higher with prolonged use and inadequate injection site rotation. The most important preventive measure is meticulous rotation of injection sites, ensuring that the same location is not used more frequently than once every seven days. Patients should be educated to identify early signs of lipoatrophy and to avoid injecting into affected areas.

How Should You Store Glatimyl?

Proper storage of Glatimyl is important to maintain the quality, stability, and efficacy of the medication. As a protein-based pharmaceutical product, glatiramer acetate is sensitive to temperature extremes, freezing, and prolonged light exposure, all of which can alter its molecular structure and potentially reduce its therapeutic effectiveness or safety.

Follow these storage guidelines carefully:

• Refrigerated storage (primary): Store Glatimyl pre-filled syringes in the refrigerator at 2–8 °C (36–46 °F). This is the recommended primary storage condition. Keep the syringes in the original outer carton to protect them from light.
• Do not freeze: Freezing can damage the protein structure of glatiramer acetate and render the medication ineffective. If a pre-filled syringe has been accidentally frozen, discard it and use a new one. Do not attempt to thaw and use a frozen syringe.
• Temporary room temperature storage: If needed (for example, during travel), Glatimyl can be stored at room temperature, up to 25 °C (77 °F), for a single period of up to one month. Once removed from the refrigerator and stored at room temperature, the syringes should not be returned to the refrigerator. Mark the date you removed them from the refrigerator and discard any unused syringes after one month at room temperature.
• Protect from light: Keep the syringes in the original carton until ready to use. Do not expose them to direct sunlight or bright artificial light for prolonged periods.
• Keep out of reach of children: Store Glatimyl in a location that is secure and inaccessible to children.
• Check expiration date: Do not use Glatimyl after the expiration date printed on the syringe label and outer carton. The expiration date refers to the last day of that month.
• Inspect before use: Before each injection, visually inspect the solution in the pre-filled syringe. The solution should be clear, colorless, and free of particulate matter. Do not use the syringe if the solution appears cloudy, discolored, or contains visible particles, or if the syringe is damaged or has been tampered with.
• Disposal: Dispose of used syringes and needles in an approved sharps disposal container. Do not dispose of used syringes in household waste or recycling. Ask your pharmacist for guidance on proper disposal of used containers.

When traveling with Glatimyl, use an insulated bag with a cold pack to maintain the appropriate temperature. If traveling by air, carry the medication in your hand luggage rather than in checked baggage to avoid exposure to extreme temperatures in the cargo hold. Airport security screening should not damage the medication. Carry a letter from your healthcare provider confirming your need for injectable medication, particularly for international travel.

What Does Glatimyl Contain?

Understanding the composition of Glatimyl is important for patients, particularly those with known allergies or sensitivities to pharmaceutical ingredients. Below is a detailed description of the active and inactive ingredients.

Active Ingredient

The active substance is glatiramer acetate, a synthetic mixture of polypeptides composed of four naturally occurring L-amino acids: glutamic acid, alanine, tyrosine, and lysine, in a defined molar ratio. The resulting mixture consists of random copolymers with an average molecular weight of 5,000–9,000 daltons. Each pre-filled syringe contains 20 mg of glatiramer acetate in 1 mL of solution (corresponding to a concentration of 20 mg/mL).

Glatiramer acetate is structurally related to myelin basic protein (MBP), one of the principal protein components of the myelin sheath in the central nervous system. This structural similarity is fundamental to its immunomodulatory mechanism of action, as it enables the drug to competitively interact with immune cells that would otherwise target myelin for destruction.

Inactive Ingredients (Excipients)

Appearance and Pack Sizes

Glatimyl is supplied as a clear, colorless solution for injection in single-use pre-filled syringes. Each syringe contains 1 mL of solution. The medication is typically available in packs of 28 pre-filled syringes, representing approximately one month of daily treatment. The syringes are fitted with a fixed needle and a needle guard that automatically covers the needle after injection to help prevent needlestick injuries. Not all pack sizes may be available in every country.

About Glatiramer Acetate Products

Glatimyl is a generic (biosimilar-like) version of the original glatiramer acetate product, Copaxone, which was first approved by the FDA in 1996 and by the EMA subsequently. Due to the complex, non-biological nature of glatiramer acetate (it is classified as a non-biological complex drug, or NBCD), regulatory pathways for generic glatiramer acetate products have required demonstration of pharmaceutical equivalence, including equivalent physicochemical properties, and in some jurisdictions, clinical data to support therapeutic equivalence. Glatimyl has been approved based on demonstration of equivalent composition, quality, and clinical performance to the reference product.